Pharmstandard to keep 2014 capex flat at 1.5 bln rubles
DOLGOPRUDNY, MOSCOW REGION. June 27 (Interfax) - Pharmstandard will keep capex level with last year in 2014 at 1.5 billion rubles, the pharmaceutical company's deputy general director for industrial projects, Yelena Arkhangelskaya, told Interfax.
During this year the company is continuing to implement a number of large projects. In particular, the company registered Johnson & Johnson's Velcade medication, adopted a full cycle of its production and concluded validation procedures, Pharmstandard's chief, Igor Krylov, said.
"If there will be demand for the product, then in Q4 we could already produce it. This development is static, large and complete," Krylov said.
Other investment projects of this scale are not planned this year, the head of the company said.
The other large project is the creation of a line of metered dose-inhalers. "The line is under contract, we are waiting for its arrival. Assembly will be continued this year and next year," Krylov said.
